Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer’s disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A?, blocking the uptake by neurons, and clearing amyloid in a subject having or at risk of developing Alzheimer’s disease or other diseases containing amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an. amyloid-beta (A?) peptide.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of neurodegenerative diseases, such as Parkinson’s disease, dementia with Lewy bodies (DLB), Alzheimer’s disease or other synucleinopathies, with alpha-synuclein deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of alpha-synuclein, blocking the uptake by neurons and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing a neurodegenerative disease containing alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising alpha-synuclein peptide.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and an alpha-synuclein peptide.

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The disclosure provides peptides, peptide compositions, immunotherapy compositions, pharmaceutical compositions and nucleic acids comprising one or more tau peptides. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases characterized at least in part by aberrant tau pathology (e.g., aggregation in neurofibrillary tangles) in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of tau, blocking the uptake by neurons, clearing tau, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau accumulations. The methods include administering to such patients the compositions comprising one or more tau peptides.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a fau. peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or oilier diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tan, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.